U.S. Markets closed

Bio-Rad Unveils Vitamin-D Test in International Market

Zacks Equity Research

Bio-Rad Laboratories, Inc. (BIO) reported the launch of the BioPlex 2200 25-OH Vitamin D kit, which will be used in the company's BioPlex 2200 system. For now, the company has launched the kit only in the international market.

The assay provides a fully-automated method for the quantitative measurement of total 25-hydroxy vitamin D in human serum. The 25-hydroxy vitamin D test is the most accurate way to determine the amount of vitamin D present in an individual's body.

A Brief Note about Vitamin D Testing

Vitamin D, a fat-soluble organic component that promotes absorption and metabolism of calcium and phosphorus in one's body, plays a crucial role in maintaining one's bone health. Recently, a number of studies validated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer.

As a result, physicians nowadays include Vitamin D testing as part of the routine assessment of their patients' overall health. This has led to substantial growth in the Vitamin D testing market, over the past several years.

Per management at Bio-Rad, the aforementioned Vitamin D kit has the potential to amplify the company's portfolio of autoimmune and infectious disease analyses.

What is BioPlex 2200 System?

Bio-Rad's BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system used for clinical diagnostic analyses that enables the detection and quantification of multiple analytes – proteins and peptides, or nucleic acids – in a single sample volume.

This system provides clinical laboratories with the capability to rapidly process multiple individual tests that are traditionally processed separately. The Bio-Plex multiplex system can multiplex up to 500 different tests simultaneously.

Zacks Rank

Bio-Rad currently has a Zacks Rank #5 (Sell). Some better-ranked medical product stocks that warrant a look are OraSure Technologies, Inc. (OSUR), Cardica Inc. (CRDC), and ICU Medical, Inc. (ICUI). While OraSure sports a Zacks Rank #1 (Strong Buy), Cardica and ICU Medical hold a Zacks Rank #2 (Buy).      


Read the Full Research Report on CRDC
Read the Full Research Report on OSUR
Read the Full Research Report on BIO
Read the Full Research Report on ICUI

Zacks Investment Research